Boston Scientific Corp. begins a trial to compare its Promus Element stent with Abbott's Xience Prime.

Boston Scientific Corp. (NYSE:BSX) set out to compare its new Promus Element drug-eluting stent system with Abbott's (ABT) Xience Prime.
The BSX-funded study will evaluate coronary revascularization outcomes in a 2,980-patient sample across 50 sites in France, Germany, Italy, Spain and the U.K.
Former iterations of the Promus line were private-label versions of Abbott’s Xience V drug-eluting stents, but the Natick, Mass.-based stent pioneer's deal to rebrand its rival's devices ended last year.
Transcatheter aortic valve implantation proves successful in reinforcing failed valve prosthetics,...
A rare but deadly genetic mutation that prevents the body from absorbing protein can be set off by...
Ohio-based medical device makers meet with local legislators to discuss efforts to repeal the...
Boston Scientific's Lotus TAVI system minimizes leakage in an early trial, St. Jude Medical gains on...
Electromed founder, chairman & CEO Robert Hansen announces his retirement after 20 years leading...